SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending amidst diverse community sentiment following its successful closing of a $1.3 billion project-level financing for a major AI/HPC data center, an event bulls view as a strong validation of its strategic pivot. While supporters see this and recent zoning approvals as foundational for future growth and a buying opportunity, others express frustration over persistent price weakness, attributing it to broader market volatility and perceived manipulation.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Bancorp, Inc. (NASDAQ:TBBK) Receives Average Recommendation of "Moderate Buy" from Analysts

The Bancorp, Inc. (NASDAQ:TBBK - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven ratings firms that are currently covering the company, MarketBeat Ratings...

Bancorp (NASDAQ:TBBK) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why

Bancorp (NASDAQ:TBBK) Stock Passes Above Two Hundred Day Moving Average - What's Next...

Invesco Ltd. Sells 57,505 Shares of The Bancorp, Inc. $TBBK

Invesco Ltd. lowered its position in shares of The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 2.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...

Edgestream Partners L.P. Reduces Stock Position in The Bancorp, Inc. $TBBK

Edgestream Partners L.P. cut its holdings in The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 69.8% during the second quarter, according to the company in its most recent 13F filing with the...

JPMorgan Chase & Co. Reduces Stock Holdings in The Bancorp, Inc. $TBBK

JPMorgan Chase & Co. reduced its position in shares of The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 31.2% in the second quarter, according to the company in its most recent filing with the...

The Bancorp, Inc. $TBBK Position Reduced by Brown Advisory Inc.

Brown Advisory Inc. decreased its position in The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 11.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned...

The Bancorp, Inc. (NASDAQ:TBBK) Given Average Recommendation of "Buy" by Brokerages

Shares of The Bancorp, Inc. (NASDAQ:TBBK - Get Free Report) have received a consensus recommendation of "Buy" from the eight analysts that are currently covering the firm, Marketbeat Ratings reports...

Loomis Sayles & Co. L P Trims Position in The Bancorp, Inc. $TBBK

Loomis Sayles & Co. L P cut its stake in shares of The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 2.4% during the 2nd quarter, according to the company in its most recent disclosure with the...

SG Americas Securities LLC Cuts Position in The Bancorp, Inc. $TBBK

SG Americas Securities LLC trimmed its holdings in shares of The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 53.5% during the second quarter, according to the company in its most recent Form 13F...

Orchard Capital Management LLC Has $6.94 Million Holdings in The Bancorp, Inc. $TBBK

Orchard Capital Management LLC reduced its position in shares of The Bancorp, Inc. (NASDAQ:TBBK - Free Report) by 42.5% during the 2nd quarter, according to the company in its most recent filing with...

The Bancorp, Inc. is a financial holding company, which engages in the provision of private label banking and financial services through the Bank. It operates through the following segments: Specialty Finance, Payments, and Corporate. The Specialty Finance segment includes the origination of non-SBA commercial real estate loans, SBA loans, direct lease financing, SBLOC, IBLOC, advisor financing, and deposits generated by those business lines. The Payments segment consists of prepaid and debit cards, card payments, automated clearing house processing, and healthcare accounts. The Corporate segment refers to the company’s investment portfolio, corporate overhead, and non-allocated expenses. The company was founded by Betzy Z. Cohen on July 20, 1999 and is headquartered in Wilmington, DE.

Current Price	$68.25
Prev Close	$68.86
Open	$68.81
Dividend Yield	0.00%
50-Day Moving Average	$67.31
Beta	1.47
Avg. Volume	592,201.32
PE Ratio	14.25

52-Week High	$81.65
52-Week Low	$40.51
Market Capitalization	$3.02B
EPS (Annual)	$4.29
Price to Book	3.91
Revenue Per Employee	$905,413.75
Enterprise Value/EBITDA	N/A

TBBK
Bancorp Inc. (The)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TBBK News

TBBKBancorp Inc. (The)